Janvi 50 Tablet
Sitagliptin
50mg
Vijayadeep Laboratories Pvt. Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 20.00 NPR |
Available as:
Indications
Janvi 50 Tablet is used for:
Type 2 diabetes mellitus
Adult Dose
Oral
Type 2 diabetes mellitus
Adult: 100 mg once daily.
Hepatic impairment
Mild to moderate impairment: Dose adjustment not necessary
Severe impairment: Not studied
Child Dose
Safety and efficacy not established
Renal Dose
Renal impairment
CrCl >50 mL/min: Dose adjustment not necessary
CrCl 30-50 mL/min: 50 mg PO qDay
CrCl <30 mL/min: 25 mg PO qDay
ESRD: 25 mg PO qDay regardless of hemodialysis
Administration
May be taken with or without food.
Contra Indications
Hypersensitivity reactions such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome can occur. Type 1 diabetes. Diabetic ketoacidosis.
Precautions
Patient w/ type 1 diabetes, history of angioedema. Not intended for the treatment of diabetic ketoacidosis. Moderate and severe renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor glycosylated Hb (HbA1c), serum glucose. Assess renal function prior to initiation of therapy and periodically thereafter.
Lactation: Not known whether excreted in breast milk: use caution
Pregnancy-Lactation
Interactions
Increased risk of hypoglycaemia when used in combination w/ sulfonylureas or insulin.
Adverse Effects
Side effects of Sitagliptin :
1-10%
Nasopharyngitis (5%),Diarrhea (4%),Headache (3.6%),Constipation (3%),Peripheral edema (2%),Nausea (2%),Pharyngitis (1%),Osteoarthritis (1%),URI (1%)
<1%
Hypersensitivity reactions such as anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis, and exfoliative skin conditions (including Stevens-Johnson syndrome)
Hepatic enzyme elevations,Acute pancreatitis, including fatal and nonfatal hemorrhagic and necrotizing pancreatitis.Constipation.Vomiting.Worsening renal function, including acute renal failure (sometimes requiring dialysis),Severe and disabling arthralgia,Myalgia,Pain in extremity,Back pain
Mechanism of Action
Sitagliptin inhibits dipeptidyl peptidase IV (DPP-IV), resulting in prolonged active incretin levels. Incretin hormones increases insulin synthesis and release from pancreatic ?-cells and reduces glucagon secretion from pancreatic ?-cells. Reduced glucagon secretion leads to decreased hepatic glucose production.
Note
Janvi 50 50mg Tablet manufactured by Vijayadeep Laboratories Pvt. Ltd.. Its generic name is Sitagliptin. Janvi 50 is availble in Nepal.
Farmaco Nepal drug index information on Janvi 50 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.